SymBio Pharmaceuticals Limited

4582・Growth Market・Pharmaceuticals

Official website

SymBio Pharmaceuticals Limited

4582・Growth Market・Pharmaceuticals

Official website

SymBio Pharmaceuticals Limited4582

Reference Indicators

Market Cap

51¥100M

P/E (Forecast)

—

P/B

4.5x

Dividend Yield (Forecast)

0.00%

ROE

-524.1%

EV/EBITDA

—

Financial Summary

Unit: ¥M

Item	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Net Sales	8,256	10,008	5,589	2,452	1,307
Cost of Sales	—	2,408	1,178	579	360
Gross Profit	5,804	7,599	4,411	1,873	947
SG&A Expenses	4,784	5,636	5,222	5,750	5,388
Operating Income	1,016	1,963	-811	-3,876	-4,440
Non-operating Income	17	139	132	224	30
Non-operating Expenses	32	102	57	37	237
Ordinary Income	1,001	1,999	-736	-3,689	-4,647
Extraordinary Income	0	106	101	14	8
Extraordinary Losses	—	—	560	131	109
Pre-tax Income	1,001	2,106	-1,195	-3,806	-4,748
Income Taxes	-1,030	927	767	26	27
Net Income	2,032	1,179	-1,962	-3,833	-4,776
EBITDA	1,109	2,061	-715	—	—
Gross Margin	70.3%	75.9%	78.9%	76.4%	72.4%
Operating Margin	12.3%	19.6%	-14.5%	-158.1%	-339.6%
ROA	24.0%	11.3%	-24.0%	-77.2%	-123.5%
ROE	39.6%	14.6%	-28.3%	-99.0%	-524.1%

Segment Performance

Unit: ¥M

2026

Segment	Net Sales	Operating Income	Operating Margin
医薬品等の研究開発及び製造販売並びにこれらの付随業務	0	0	0.0%